Reduced-Dose Thrombolysis in Intermediate-Risk Pulmonary Embolism With High-Risk Features

A phase 3 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 270 participants.

Also called NCT07917078

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 270 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT07917078
Planned start
(anticipated) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Not yet recruiting (from the registry)

Technical summary

Registry record NCT07917078. Randomized; single masking; primary purpose treatment. Start 2026-11-01 (anticipated); primary completion 2028-12-31 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Reduced-Dose Thrombolysis in Intermediate-Risk Pulmonary Embolism With High-Risk Features
Acronym
REDUCTION
Intervention (Drug)
Alteplase
Intervention (Drug)
Standard Anticoagulation
Lead sponsor
China National Center for Cardiovascular Diseases (class: other government)

Record details

Record id
cardio:ct-nct07917078
Content hash
f877fbab28bd8d1d9eb5d9edc8943108f65b69684e5307258f25894f1db3721a